{
  "id": "cluster_0_doc3",
  "content": "AGTO-2217 research update shows 78% efficacy in neuropathy reduction among participants with concomitant immunodeficiency. Study cohort includes 12 patients from Polk Health Network, half over age 50. Notable outlier: one male participant (patient ID PX-908712) required extended immunotherapy beyond protocol guidelines.",
  "metadata": {
    "format": "research_note"
  }
}